BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25081726)

  • 21. Systemic therapy for pancreatic cancer.
    Ko AH; Tempero MA
    Semin Radiat Oncol; 2005 Oct; 15(4):245-53. PubMed ID: 16183478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
    Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
    Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
    Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
    Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
    Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
    Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
    Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.
    Lièvre A; Samalin E; Mitry E; Assenat E; Boyer-Gestin C; Lepère C; Bachet JB; Portales F; Vaillant JN; Ychou M; Rougier P
    BMC Cancer; 2009 Sep; 9():347. PubMed ID: 19785749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
    Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
    Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U
    Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program.
    Atkins JN; Jacobs SA; Wieand HS; Smith RE; John WJ; Colangelo LH; Vogel VG; Kuebler JP; Cescon TP; Miller BJ; Geyer CE; Wolmark N
    Clin Colorectal Cancer; 2005 Sep; 5(3):181-7. PubMed ID: 16197621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
    Spigel DR; Hainsworth JD; Shipley DL; Ervin TJ; Kohler PC; Lubiner ET; Peyton JD; Waterhouse DM; Burris HA; Greco FA
    J Thorac Oncol; 2012 Jan; 7(1):196-202. PubMed ID: 21900836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
    Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
    Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
    Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
    Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
    Lee KW; Kim YJ; Lee KH; Han SW; Kim TY; Oh DY; Im SA; Kim TY; Bang YJ; Choi IS; Kim JH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):447-55. PubMed ID: 24947909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New oxaliplatin-based combinations in the treatment of colorectal cancer.
    Cassidy J; Hochster H
    Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.
    Le Chevalier T
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):37-44. PubMed ID: 12947960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer.
    Hochster H; Kettner E; Kroning H; Becker K; Lordick F; Ramanathan RK; Macdonald J; Hong S; John W; Schmoll HJ
    Clin Colorectal Cancer; 2005 Nov; 5(4):257-62. PubMed ID: 16356302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.
    Sato Y; Hirakawa M; Ohnuma H; Takahashi M; Okamoto T; Okamoto K; Miyamoto H; Muguruma N; Furuhata T; Takemasa I; Kato J; Takayama T
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1133-1139. PubMed ID: 29038850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pemetrexed in the treatment of advanced non-squamous lung cancer.
    Rossi A; Ricciardi S; Maione P; de Marinis F; Gridelli C
    Lung Cancer; 2009 Nov; 66(2):141-9. PubMed ID: 19577816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
    Figueras J; Lopez-Ben S; Alsina M; Soriano J; Hernandez-Yagüe X; Albiol M; Guardeño R; Codina-Barreras A; Queralt B
    Clin Transl Oncol; 2013 Jun; 15(6):460-6. PubMed ID: 23143951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.